Supreme Court Report

Supreme Court of the United States · Official docket →

Teva Pharmaceuticals USA, Inc. v. Stephen Wendell, et al.

Paid petition · United States Court of Appeals for the Ninth Circuit, No. 14-16321 · judgment June 2, 2017


Certiorari denied · March 19, 2018
Pre-decision estimate: 12% cert probability (95% interval 9%–16%)

Before the decision, about 3× the 4.1% base rate. The model weighted this up for a Ninth Circuit decision below, a circuit split argued in the petition, and a dissent in the court below (flagged in the petition).

Questions presented

The admissibility of expert testimony is governed by Rule 702 of the Federal Rules of Evidence. Rule 702 provides that “[a] witness who is qualified as an expert . . . may testify in the form of an opinion or otherwise if,” among other things, “the testimony is the product of reliable principles and methods” and “the testimony has reliably applied the principles and methods to the facts of the case.” Fed. R. Evid. 702(c), (d) (emphasis added). This Court has held that a district court’s application of Rule 702 is reviewed for abuse of discretion. Gen. Elec. Co. v. Joiner, 522 U.S. 136, 143 (1997). The questions presented are as follows:

  1. Whether the two-part standard of reviewing expert-admissibility rulings employed by the Ninth Circuit, along with the Third and Seventh Circuits, improperly empowers these courts to reverse district court decisions to exclude evidence without “the deference that is the hallmark of abuse-of-discretion review.” Joiner, 522 U.S. at 143.

  2. Whether an expert’s qualifications and mere invocation of a scientific methodology can be sufficient to require admission of his testimony, as the Ninth Circuit concluded, or whether Rule 702 requires that a witness, no matter how qualified, must also satisfy the court that his methodology was “reliably applied to the facts of the case,” as several other circuits have held.

Counsel of record

For petitioner
William McGinley Jay
Goodwin Procter, LLP

For respondent
Alan Jay Lazarus
Faegre Drinker, Biddle & Reath, LLP

Case

Conference history
Distributed for 1 conference

Amicus briefs
2 cert-stage

Linked docket
17A376

Proceedings

  1. Mar 19 2018
    Petition DENIED.
  2. Feb 21 2018
    DISTRIBUTED for Conference of 3/16/2018.
  3. Feb 20 2018
    Reply of petitioner Teva Pharmaceuticals USA, Inc. filed.
  4. Feb 02 2018
    Brief of respondents Stephen Wendell, et ux. in opposition filed.
  5. Jan 08 2018
    Motion to extend the time to file a response is granted and the time is further extended to and including February 2, 2018.
  6. Jan 03 2018
    Motion to extend the time to file a response from January 19, 2018 to February 2, 2018, submitted to The Clerk.
  7. Dec 20 2017
    Brief amicus curiae of The Chamber of Commerce of the United States of America filed.
  8. Dec 20 2017
    Brief amicus curiae of DRI-The Voice of the Defense Bar filed.
  9. Dec 18 2017
    Brief of respondent GlaxoSmithKline LLC in support filed.
  10. Dec 14 2017
    Motion to extend the time to file a response is granted and the time is extended to and including January 19, 2018.
  11. Dec 08 2017
    Motion to extend the time to file a response from December 20, 2017 to January 19, 2018, submitted to The Clerk.
  12. Nov 20 2017
    Petition for a writ of certiorari filed. (Response due December 20, 2017)
  13. Oct 05 2017
    Application (17A376) granted by Justice Kennedy extending the time to file until November 20, 2017.
  14. Oct 04 2017
    Application (17A376) to extend the time to file a petition for a writ of certiorari from October 19, 2017 to November 20, 2017, submitted to Justice Kennedy.